BrightEdge is the donor-funded innovation, impact investment, and venture capital arm of the American Cancer Society. It invests in for-profit, early-stage companies developing cancer-focused therapeutics, diagnostics, medical devices, and technologies to advance the ACS mission to eradicate cancer.
35% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $53.4M (across 19 rounds with reported amounts).
Portfolio
19
Fund Size
$80.3M
Top Stage
Series B
Last 12 Mo
0
Team
Steve Curtis,PhD
Managing Director
Barbra Kocsis,MBA, MA
Director, Operations
Farnaz Bakhshi,PhD
Director, Innovation
Michka Sharpe,PhD
Senior Associate, Investments
Nate Macht,MBA
Investment and Innovation Senior Analyst
Ana Rojas
Executive Assistant
Carolyn Simmons
Operations and Events Coordinator
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Alpheus Medical | Series B | $52M | May 2025 |
| AAlpheus | Series B | $52M | May 2025 |
 CellCentric | Series C | $120M | Jan 2025 |
 TippingPoint Biosciences | Pre-Seed | — | Sep 2024 |
| MModifi Biosciences | Seed | $4.3M | Oct 2023 |
 Thatch | Seed | $6M | Feb 2023 |
 Auron Therapeutics | Series A | $48M | Jul 2022 |
 Meliora Therapeutics | Seed | $11M | Jan 2022 |
 Immunitas Therapeutics | Series B | $58M | Aug 2021 |
| IImmunitas | Series B | $58M | Aug 2021 |
 Interius BioTherapeutics | Series A | $76M | May 2021 |
| IImmunitas | Series B | $58M | Jan 2021 |
| TTmunity | Series B | $75M | Oct 2019 |
 Tmunity Therapeutics | Series B | $75M | Oct 2019 |
 Freenome Inc | Series C | $160M | Jul 2019 |
 Navigating Cancer | Series D | $10M | Aug 2015 |
 TailorMed | Unknown | $40M | — |
| CCheckmate Pharmaceuticals | Series C | $85M | — |
 Signify Bio | Unknown | $15M | — |
 Meliora | Seed | $11M | — |
Top Co-Investors
Last updated: 8 September 2026